Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development

2017 ◽  
Vol 106 (8) ◽  
pp. 1971-1977 ◽  
Author(s):  
Deborah S. Goldberg ◽  
Rachael A. Lewus ◽  
Reza Esfandiary ◽  
David C. Farkas ◽  
Neil Mody ◽  
...  
2019 ◽  
Vol 25 (1) ◽  
pp. 9-20 ◽  
Author(s):  
Olivia W. Lee ◽  
Shelley Austin ◽  
Madison Gamma ◽  
Dorian M. Cheff ◽  
Tobie D. Lee ◽  
...  

Cell-based phenotypic screening is a commonly used approach to discover biological pathways, novel drug targets, chemical probes, and high-quality hit-to-lead molecules. Many hits identified from high-throughput screening campaigns are ruled out through a series of follow-up potency, selectivity/specificity, and cytotoxicity assays. Prioritization of molecules with little or no cytotoxicity for downstream evaluation can influence the future direction of projects, so cytotoxicity profiling of screening libraries at an early stage is essential for increasing the likelihood of candidate success. In this study, we assessed the cell-based cytotoxicity of nearly 10,000 compounds in the National Institutes of Health, National Center for Advancing Translational Sciences annotated libraries and more than 100,000 compounds in a diversity library against four normal cell lines (HEK 293, NIH 3T3, CRL-7250, and HaCat) and one cancer cell line (KB 3-1, a HeLa subline). This large-scale library profiling was analyzed for overall screening outcomes, hit rates, pan-activity, and selectivity. For the annotated library, we also examined the primary targets and mechanistic pathways regularly associated with cell death. To our knowledge, this is the first study to use high-throughput screening to profile a large screening collection (>100,000 compounds) for cytotoxicity in both normal and cancer cell lines. The results generated here constitute a valuable resource for the scientific community and provide insight into the extent of cytotoxic compounds in screening libraries, allowing for the identification and avoidance of compounds with cytotoxicity during high-throughput screening campaigns.


mAbs ◽  
2013 ◽  
Vol 6 (2) ◽  
pp. 483-492 ◽  
Author(s):  
Yuqi Liu ◽  
Isabelle Caffry ◽  
Jiemin Wu ◽  
Steven B Geng ◽  
Tushar Jain ◽  
...  

2018 ◽  
Author(s):  
Olivia W. Lee ◽  
Shelley Austin ◽  
Madison Gamma ◽  
Dorian M. Cheff ◽  
Tobie D. Lee ◽  
...  

AbstractCell-based phenotypic screening is a commonly used approach to discover biological pathways, novel drug targets, chemical probes and high-quality hit-to-lead molecules. Many hits identified from high-throughput screening campaigns are ruled out through a series of follow-up potency, selectivity/specificity, and cytotoxicity assays. Prioritization of molecules with little or no cytotoxicity for downstream evaluation can influence the future direction of projects, so cytotoxicity profiling of screening libraries at an early stage is essential for increasing the likelihood of candidate success. In this study, we assessed cell-based cytotoxicity of nearly 10,000 compounds in NCATS annotated libraries, and over 100,000 compounds in a diversity library, against four ‘normal’ cell lines (HEK 293, NIH 3T3, CRL-7250 and HaCat) and one cancer cell line (KB 3-1, a HeLa subline). This large-scale library profiling was analyzed for overall screening outcomes, hit rates, pan-activity and selectivity. For the annotated library, we also examined the primary targets and mechanistic pathways regularly associated with cell death. To our knowledge, this is the first study to use high-throughput screening to profile a large screening collection (>100,000 compounds) for cytotoxicity in both normal and cancer cell lines. The results generated here constitutes a valuable resource for the scientific community and provides insight on the extent of cytotoxic compounds in screening libraries, identifying and avoiding compounds with cytotoxicity during high-throughput screening campaigns.


Author(s):  
P. Desrosiers ◽  
E. Carlson ◽  
W. Chandler ◽  
H. Chau ◽  
P. Cong ◽  
...  

2021 ◽  
Author(s):  
Moataz Dowaidar

High throughput screening techniques have facilitated the creation of RNA treatments, and these findings have been accompanied by unique modifications of RNA structures to increase stability and minimize toxicity, as well as innovative delivery systems such as LNPs. "undruggable" targets, "swiftly construct vaccinations," and to provide therapeutic approaches that can be tailored to individual patients Like the genetic code, RNA therapies hold great promise.At the same time, our hospital launched a specialized RNA Therapeutics program that assists both our internal scientists and external academic groups or small firms aiming to apply their fundamental research discoveries to innovative treatments. mRNA is primarily stable because of our primary study in sequencing and structure. For synthesis, purification, and validation of RNA constructs, we have a contemporary GMP program with clean rooms. Our company collaborates with Nanomedicine to build LNP structures that transport mRNA constructs locally and systemically. We have an opportunity to hire and integrate first-in-man clinical trials unit, as well as a big hospital system with a clinical research infrastructure that enables industry-sponsored Phase 2 and 3 clinical trials. Additionally, we have a large-scale mRNA construction industrial sponsor for Phases 2, 3, and commercialization. Essentially, we've put up a production line for universities and small firms interested in turning their mRNA creations into revolutionary medications. One hospital, one point of entry to ensure that RNA-based drugs are created and translated into the clinic efficiently. Many tiny firms with fresh concepts for disruptive mRNA therapeutics cannot reach the clinic without new translational capabilities. We think we are the only academic organization with the infrastructure to help small academic groups and biotech enterprises, and we want to aid both internal and external translational activities in the coming years.


Sign in / Sign up

Export Citation Format

Share Document